AGGRASTAT 12.5 MG / 250 ML
TIROFIBAN (TIROFIBAN HYDROCHLORIDE) : 12.5 MG / 250 ML · DIN 02240706 · CIPHER PHARMACEUTICALS INC
Health Canada status: MARKETED
What is AGGRASTAT?
AGGRASTAT 12.5 MG / 250 ML contains TIROFIBAN (TIROFIBAN HYDROCHLORIDE) : 12.5 MG / 250 ML. It is listed in the Health Canada Drug Product Database under DIN 02240706, held by CIPHER PHARMACEUTICALS INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 29-Jul-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AGGRASTAT used for?
AGGRASTAT is indicated for the management of adult patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) including patients who may subsequently undergo percutaneous coronary intervention (PCI) to decrease the rate of refractory ischemic conditions, new myocardial infarction and death. AGGRASTAT is intended for use in combination with anticoagulants (e.g. heparin) and other antiplatelet therapies, including acetylsalicylic acid (ASA).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02240706 |
|---|---|
| Brand name | AGGRASTAT |
| Generic / active ingredient | TIROFIBAN (TIROFIBAN HYDROCHLORIDE) : 12.5 MG / 250 ML |
| Manufacturer | CIPHER PHARMACEUTICALS INC |
| Strength | 12.5 MG / 250 ML |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | B01AC17 TIROFIBAN |
| AHFS class | 20:12.18 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 29-Jul-2021 |
| Original market date | 2002-05-01 00:00:00 |
How is it stored and handled?
null
How is it supplied?
250 mL bags
What can be used instead?
Other Canadian products sharing ATC code B01AC17 TIROFIBAN. 1 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AGGRASTAT | 0.25 MG | LIQUID | CORREVIO (UK) LTD | CANCELLED POST MARKET | DIN 02240705 |
Who else supplies TIROFIBAN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TIROFIBAN appears in 20 registered pack listings across 8 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.